Literature DB >> 7509437

Cloning and expression of the alpha 2C-adrenergic receptor from the OK cell line.

H S Blaxall1, D R Cerutis, N A Hass, L J Iversen, D B Bylund.   

Abstract

The alpha 2-adrenergic receptors have been divided into four pharmacological subtypes, alpha 2A, alpha 2B, alpha 2C, and alpha 2D. The OK cell line, a cell line derived from an opossum kidney, expresses the alpha 2C-adrenergic receptor and is the prototypical cell line for the alpha 2C receptor subtype. The cloned human alpha 2C-C4 and rat RG10 receptors have been shown to express alpha 2C pharmacology. Here we report the cloning and expression of the OK alpha 2C-adrenergic receptor, OKc2. The receptor has 64% deduced amino acid identity and 21% similarity to the alpha 2-C4 receptor, giving an overall similarity of 85%. The clone, expressed in Chinese hamster ovary cells, has a pharmacology that correlates very well (r = 0.97) with that of the native OK cell alpha 2C-adrenergic receptor, and it is negatively coupled to adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509437

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

1.  Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2.

Authors:  C Cayla; S Schaak; C Roquelaine; C Gales; F Quinchon; H Paris
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  G protein-coupled receptors regulate Na+,K+-ATPase activity and endocytosis by modulating the recruitment of adaptor protein 2 and clathrin.

Authors:  G Ogimoto; G A Yudowski; C J Barker; M Köhler; A I Katz; E Féraille; C H Pedemonte; P O Berggren; A M Bertorello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

3.  Down-regulation of the alpha-2C adrenergic receptor: involvement of a serine/threonine motif in the third cytoplasmic loop.

Authors:  Jean D Deupree; Claudia D Borgeson; David B Bylund
Journal:  BMC Pharmacol       Date:  2002-04-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.